Lyell Immunopharma (LYEL) Current Deferred Revenue (2020 - 2022)

Lyell Immunopharma (LYEL) has 3 years of Current Deferred Revenue data on file, last reported at $11.2 million in Q3 2022.

• For the quarter ending Q3 2022, Current Deferred Revenue rose 100.52% year-over-year to $11.2 million; the trailing twelve-month figure through Sep 2022 stood at $11.2 million (up 100.52% YoY), and the FY2021 full-year result was $5.0 million, down 88.92% from the prior year.
• Current Deferred Revenue declined to $11.2 million in Q3 2022, from $15.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $45.0 million in Q4 2020 to a low of $5.0 million in Q4 2021.
• A 3-year average of $13.8 million and a median of $8.2 million in 2021 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue sank 88.92% in 2021 and soared 100.52% in 2022, its largest moves.
• Tracing LYEL's Current Deferred Revenue over 3 years: stood at $45.0 million in 2020, then slumped by 88.92% to $5.0 million in 2021, then surged by 124.36% to $11.2 million in 2022.
• Business Quant data shows LYEL's Current Deferred Revenue at $11.2 million in Q3 2022, $15.4 million in Q2 2022, and $6.2 million in Q1 2022.